1993 Fiscal Year Final Research Report Summary
Studies on Adoptive Immunotherapy Utilizing Allogeneic Spleen Cells Against Cancers
| Project/Area Number |
03670949
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
外科・放射線系歯学
|
|---|
| Research Institution | Saga Medical School |
|---|
Principal Investigator |
KUBOTA Eiro Saga Medical School, Assistant Professor, 医学部, 講師 (50170030)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATANO Mitsuo Saga Medical School, Assistant Professor, 医学部, 講師 (10145203)
KUROKAWA Hiroyuki Saga Medical School, Resident, 医学部, 助手 (70225283)
NAKAGAWA Hirotoshi Saga Medical School, Resident, 医学部, 助手 (20217681)
GOTO Masaki Saga Medical School, Associate Professor, 医学部, 助教授 (10145211)
KATSUKI Takeshi Saga Medical School, Professor, 医学部, 教授 (70038868)
|
|---|
| Project Period (FY) |
1991 – 1993
|
| Keywords | Allogeneic spleen cells / Killer cells / Anti-tumor cytokine / Adoptive immunotherapy / Head and neck cancer |
|---|
| Research Abstract |
Culture of peripheral blood mononuclear cells(PBMC) with a heat and penicillin-treated streptococcal preparation, OK-432 has induced effector cells which have both cell-mediated and cytokine-mediated antitumor activities. The cell-mediated activities were attributed to natural killer(NK) cells and lymphokine activated killer(LAK) cells. The cytokine-mediated activities were mainly due to production of tumor growth inhibitory factor(TGIF), which was distinct from other cytokines and was synergize with IFN gamma. Frozen-stored human spleen cells cultured with OK-432(OK-SP) also acquired direct cytotoxicity to autologous as well as allogeneic tumor cells. The activated cells started to produce cytocidal cytokines such as TGIF and IFN gamma.
These OK-MC and OK-SP were adoptively transferred into head and neck cancer patients in combination with chemotherapy and/or radiation therapy, and their therapeutic effects were examined. AIT was performed by intra-arterial or intratumoral administration of these cells. Of the 17 patients who received OK-MC, 6 of them(6/17 ; 35%) was obtained complete remission(CR) of the tumor, and partial remission(PR) was attained in 9 of the 17(9/17 ; 53%). Furthermore, complete disappearance of the tumor cells was observed in 4 of CR cases and 4 of the 9 PR patients. OK-SP were also injected into two cancer patients. In these patients, PR was obtained in one case and the other had MR with rapid necrosis of cancer tissue and remarkable decrease of tumor markers. There were no severe side effects. These results indicate the feasibility in using allogeneic spleen cells for adoptive local immunotherapy.
|
Research Products
(16 results)
-
-
-
-
-
-
-
-
-
[Publications] Katano M, Kubota E, Yamamoto H, Nakamura M, Matsuo T, Hisatsugu T, Katsuki T, Koga H, Ikezaki K, Tabuchi K, Nagumo F, and Tadano J.: "A possible clinical application of multicytokine-producing cytotoxic mononuclear cell (MCCM) therapy." Biotherapy. 3. 373-379 (1991)
Description
「研究成果報告書概要(欧文)」より
-
-
-
-
-
-
-
